Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Merck’s Keytruda Cuts Death Risk by 31 Percent in Esophageal Cancer

Merck & Co. released data from KEYNOTE-181, a Phase III trial of Keytruda as a monotherapy for the second-line treatment of advanced or metastatic esophageal or esophagogastric junction carcinoma.

Read More »

Pfizer Cuts 150 Jobs, Along With Broader R&D Reconfigurations

Pfizer is ending five preclinical programs in the biosimilar area and cutting 150 positions in Lake Forest, Illinois and in Chennai, India.

Read More »

AI Discovers Misshapen Cells in Ovarian Cancer Patients That Present New Drug Targets

Artificial intelligence technology has an established home in drug design for many developers. Now, researchers are seeing AI technology as a potential tool in driving therapeutic choices in the treatment of ovarian cancer.

Read More »

U.S. substance abuse helpline largely unknown

The U.S. government’s toll-free substance abuse helpline, which provides free referral services to those looking for treatment, gets little publicity, a new study finds.

Read More »

Statins may help prevent diabetes-related eye problems

Diabetic patients who take statins to treat high cholesterol may get an added benefit: a lower risk of damage to the retina, a new study suggests.

Read More »

Alzheimer’s: New Approaches and New Hope

Unfortunately, 2018 marked yet another bad year for Alzheimer’s disease drug development, with at least half-a-dozen major clinical drug trial failures.

Read More »

Elevian and Insilico Enter a Research Collaboration to Discover Drugs That Target Aging

Two leading longevity biotechnology companies, Elevian and Insilico Medicine, announced a research and development partnership to develop oral medications targeting the GDF11 pathway and associated targets.

Read More »

After Announcing a New CEO, UroGen Touts Positive Phase III Data for Urothelial Cancer

UroGen Pharma announced positive top-line results from the New York based-company’s Phase III OLYMPUS clinical trial that evaluated UGN-101 (mitomycin gel) for instillation for the non-surgical treatment of low-grade upper tract urothelial cancer.

Read More »

Pixium Vision announces its PRIMA chip successfully met interim study endpoints for dry AMD

Pixium Vision announced that the bioelectronics company’s subretinal PRIMA system met the endpoints of the feasibility study, at interim 6 months follow-up after implantation and rehabilitation for patients with advanced dry age-related macular degeneration (AMD).

Read More »

Sage shares soar after oral postpartum depression treatment succeeds in trial

Sage Therapeutics’ postpartum depression oral treatment met the main goal of reducing the condition’s symptoms versus a placebo in a late-stage study, sending the drugmaker’s shares up 33 percent.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

December 2018 Focus: Healthcare Agency Roundtable, Mobile Marketing, and more!

Subscribe

Ad Right Bottom